ACTRN12605000705684招募中3 期
A prospective randomised phase III trial evaluating the effect of more intensive information on patient satisfaction and anxiety.
Perth Radiation Oncology Centre0 个研究点目标入组 212 人开始时间: 2005年11月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 212
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Educational / counselling / training
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •The patient must be having radical radiotherapy.The patient must have a good understanding of english.The patient must be able to complete questionnaire unaided.Used only for patients diagnosed with Breast,Lung,Prostate,Rectal and Gynaecological cancer.
排除标准
- •A poor understanding of written english.Significant visual impairment and previous radiation therapy.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 14.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-FRAGO Research GmbH796
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 19.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-DKAGO Research GmbH796
进行中（未招募）
1 期
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-DEAGO Research GmbH900
进行中（未招募）
1 期
The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) TrialEpithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, FIGO Stages IIb-IVMedDRA version: 14.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001015-32-FIJohanna Mäenpää796
进行中（未招募）
1 期
The aim of this trial, which is called FRAGMATIC, is to assess the effect of adding a blood thinning drug called dalteparin (FRAGMIN®) for 24 weeks to standard treatment for patients with lung cancer to see if if has any affect on survival.ung cancerMedDRA version: 14.1 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-002438-37-GBVelindre NHS Trust2,202